Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

IRAK1 and IRAK4 promote phosphorylation, ubiquitination, and degradation of MyD88 adaptor-like (Mal).

Dunne A, Carpenter S, Brikos C, Gray P, Strelow A, Wesche H, Morrice N, O'Neill LA.

J Biol Chem. 2016 Nov 18;291(47):24802. No abstract available.

2.

Sphingosine kinase activity is not required for tumor cell viability.

Rex K, Jeffries S, Brown ML, Carlson T, Coxon A, Fajardo F, Frank B, Gustin D, Kamb A, Kassner PD, Li S, Li Y, Morgenstern K, Plant M, Quon K, Ruefli-Brasse A, Schmidt J, Swearingen E, Walker N, Wang Z, Watson JE, Wickramasinghe D, Wong M, Xu G, Wesche H.

PLoS One. 2013 Jul 5;8(7):e68328. doi: 10.1371/journal.pone.0068328. Print 2013.

3.

Structure guided design of a series of sphingosine kinase (SphK) inhibitors.

Gustin DJ, Li Y, Brown ML, Min X, Schmitt MJ, Wanska M, Wang X, Connors R, Johnstone S, Cardozo M, Cheng AC, Jeffries S, Franks B, Li S, Shen S, Wong M, Wesche H, Xu G, Carlson TJ, Plant M, Morgenstern K, Rex K, Schmitt J, Coxon A, Walker N, Kayser F, Wang Z.

Bioorg Med Chem Lett. 2013 Aug 15;23(16):4608-16. doi: 10.1016/j.bmcl.2013.06.030. Epub 2013 Jun 20.

PMID:
23845219
4.

Pillars article: MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity. 1997. 7: 837-847.

Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z.

J Immunol. 2013 Jan 1;190(1):5-15. No abstract available.

5.

Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.

Jiao X, Kopecky DJ, Liu J, Liu J, Jaen JC, Cardozo MG, Sharma R, Walker N, Wesche H, Li S, Farrelly E, Xiao SH, Wang Z, Kayser F.

Bioorg Med Chem Lett. 2012 Oct 1;22(19):6212-7. doi: 10.1016/j.bmcl.2012.08.020. Epub 2012 Aug 10.

PMID:
22929232
6.

A novel series of IKKβ inhibitors part I: Initial SAR studies of a HTS hit.

Cushing TD, Baichwal V, Berry K, Billedeau R, Bordunov V, Broka C, Cardozo M, Cheng P, Clark D, Dalrymple S, DeGraffenreid M, Gill A, Hao X, Hawley RC, He X, Jaen JC, Labadie SS, Labelle M, Lehel C, Lu PP, McIntosh J, Miao S, Parast C, Shin Y, Sjogren EB, Smith ML, Talamas FX, Tonn G, Walker KM, Walker NP, Wesche H, Whitehead C, Wright M, Browner MF.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):417-22. doi: 10.1016/j.bmcl.2010.10.126. Epub 2010 Oct 29.

PMID:
21074993
7.

A novel series of IKKβ inhibitors part II: description of a potent and pharmacologically active series of analogs.

Cushing TD, Baichwal V, Berry K, Billedeau R, Bordunov V, Broka C, Browner MF, Cardozo M, Cheng P, Clark D, Dalrymple S, DeGraffenreid M, Gill A, Hao X, Hawley RC, He X, Labadie SS, Labelle M, Lehel C, Lu PP, McIntosh J, Miao S, Parast C, Shin Y, Sjogren EB, Smith ML, Talamas FX, Tonn G, Walker KM, Walker NP, Wesche H, Whitehead C, Wright M, Jaen JC.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):423-6. doi: 10.1016/j.bmcl.2010.10.125. Epub 2010 Oct 29.

PMID:
21074992
8.

Molecular signatures of the primitive prostate stem cell niche reveal novel mesenchymal-epithelial signaling pathways.

Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, Wesche H, Marshall L, Cutler G, Wang X, Zavadil J, Moscatelli D, Wilson EL.

PLoS One. 2010 Sep 30;5(9). pii: e13024. doi: 10.1371/journal.pone.0013024.

9.

IRAK1 and IRAK4 promote phosphorylation, ubiquitination, and degradation of MyD88 adaptor-like (Mal).

Dunne A, Carpenter S, Brikos C, Gray P, Strelow A, Wesche H, Morrice N, O'Neill LA.

J Biol Chem. 2010 Jun 11;285(24):18276-82. doi: 10.1074/jbc.M109.098137. Epub 2010 Apr 16. Erratum in: J Biol Chem. 2016 Nov 18;291(47):24802.

10.

IRAK-4 inhibitors for inflammation.

Wang Z, Wesche H, Stevens T, Walker N, Yeh WC.

Curr Top Med Chem. 2009;9(8):724-37. Review.

11.

Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer.

Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, Wesche H, Marshall L, Cutler G, Wang X, Zavadil J, Moscatelli D, Wilson EL.

PLoS One. 2009 May 29;4(5):e5722. doi: 10.1371/journal.pone.0005722.

12.

Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.

Kopecky DJ, Hao X, Chen Y, Fu J, Jiao X, Jaen JC, Cardozo MG, Liu J, Wang Z, Walker NP, Wesche H, Li S, Farrelly E, Xiao SH, Kayser F.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6352-6. doi: 10.1016/j.bmcl.2008.10.092. Epub 2008 Nov 1.

PMID:
18993068
13.

The growth factor Midkine antagonizes VEGF signaling in vitro and in vivo.

van der Horst EH, Frank BT, Chinn L, Coxon A, Li S, Polesso F, Slavin A, Ruefli-Brasse A, Wesche H.

Neoplasia. 2008 Apr;10(4):340-7.

14.

"Spirit" of high throughput screening.

Wesche H, Xiao SH, Young S.

Comb Chem High Throughput Screen. 2008 Mar;11(3):174. No abstract available.

PMID:
18336210
15.

Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents.

Beck HP, Kohn T, Rubenstein S, Hedberg C, Schwandner R, Hasslinger K, Dai K, Li C, Liang L, Wesche H, Frank B, An S, Wickramasinghe D, Jaen J, Medina J, Hungate R, Shen W.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1037-41. doi: 10.1016/j.bmcl.2007.12.024. Epub 2008 Jan 4.

PMID:
18178086
16.

An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated protein tyrosine kinase ACK1.

Xiao SH, Farrelly E, Anzola J, Crawford D, Jiao X, Liu J, Ayres M, Li S, Huang L, Sharma R, Kayser F, Wesche H, Young SW.

Anal Biochem. 2007 Aug 15;367(2):179-89. Epub 2007 May 10.

PMID:
17592719
17.

Burnout and effort-reward-imbalance in a sample of 949 German teachers.

Unterbrink T, Hack A, Pfeifer R, Buhl-Griesshaber V, Müller U, Wesche H, Frommhold M, Scheuch K, Seibt R, Wirsching M, Bauer J.

Int Arch Occup Environ Health. 2007 Apr;80(5):433-41. Epub 2007 Feb 10.

PMID:
17294239
18.

Working conditions, adverse events and mental health problems in a sample of 949 German teachers.

Bauer J, Unterbrink T, Hack A, Pfeifer R, Buhl-Griesshaber V, Müller U, Wesche H, Frommhold M, Seibt R, Scheuch K, Wirsching M.

Int Arch Occup Environ Health. 2007 Apr;80(5):442-9. Epub 2007 Feb 10.

PMID:
17294238
19.

Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper.

Wang Z, Liu J, Sudom A, Ayres M, Li S, Wesche H, Powers JP, Walker NP.

Structure. 2006 Dec;14(12):1835-44.

20.

Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.

Powers JP, Li S, Jaen JC, Liu J, Walker NP, Wang Z, Wesche H.

Bioorg Med Chem Lett. 2006 Jun 1;16(11):2842-5. Epub 2006 Mar 24.

PMID:
16563752
21.

Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1.

van der Horst EH, Degenhardt YY, Strelow A, Slavin A, Chinn L, Orf J, Rong M, Li S, See LH, Nguyen KQ, Hoey T, Wesche H, Powers S.

Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15901-6. Epub 2005 Oct 24.

22.

High throughput screening for protein kinase inhibitors.

Wesche H, Xiao SH, Young SW.

Comb Chem High Throughput Screen. 2005 Mar;8(2):181-95. Review. Erratum in: Comb Chem High Throughput Screen. 2005 Aug;8(5):455.

PMID:
15777182
23.

Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling.

Kollewe C, Mackensen AC, Neumann D, Knop J, Cao P, Li S, Wesche H, Martin MU.

J Biol Chem. 2004 Feb 13;279(7):5227-36. Epub 2003 Nov 18.

25.

Characterization of Pellino2, a substrate of IRAK1 and IRAK4.

Strelow A, Kollewe C, Wesche H.

FEBS Lett. 2003 Jul 17;547(1-3):157-61.

26.

Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family.

Martin MU, Wesche H.

Biochim Biophys Acta. 2002 Nov 11;1592(3):265-80. Review.

27.

IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase.

Li S, Strelow A, Fontana EJ, Wesche H.

Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5567-72.

28.

Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4.

Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, Takada H, Wakeham A, Itie A, Li S, Penninger JM, Wesche H, Ohashi PS, Mak TW, Yeh WC.

Nature. 2002 Apr 18;416(6882):750-6. Epub 2002 Mar 31.

PMID:
11923871
29.

Identification of essential regions in the cytoplasmic tail of interleukin-1 receptor accessory protein critical for interleukin-1 signaling.

Radons J, Gabler S, Wesche H, Korherr C, Hofmeister R, Falk W.

J Biol Chem. 2002 May 10;277(19):16456-63. Epub 2002 Mar 5.

30.

Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice.

Yin L, Wu L, Wesche H, Arthur CD, White JM, Goeddel DV, Schreiber RD.

Science. 2001 Mar 16;291(5511):2162-5.

31.

Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2.

Hirschfeld M, Kirschning CJ, Schwandner R, Wesche H, Weis JH, Wooten RM, Weis JJ.

J Immunol. 1999 Sep 1;163(5):2382-6.

32.

IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family.

Wesche H, Gao X, Li X, Kirschning CJ, Stark GR, Cao Z.

J Biol Chem. 1999 Jul 2;274(27):19403-10.

33.

Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2.

Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ.

J Biol Chem. 1999 Jun 18;274(25):17406-9.

34.

The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness.

Lang D, Knop J, Wesche H, Raffetseder U, Kurrle R, Boraschi D, Martin MU.

J Immunol. 1998 Dec 15;161(12):6871-7.

35.

Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide.

Kirschning CJ, Wesche H, Merrill Ayres T, Rothe M.

J Exp Med. 1998 Dec 7;188(11):2091-7.

37.

Effects of IL-1 receptor accessory protein on IL-1 binding.

Wesche H, Resch K, Martin MU.

FEBS Lett. 1998 Jun 16;429(3):303-6.

38.

MyD88: an adapter that recruits IRAK to the IL-1 receptor complex.

Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z.

Immunity. 1997 Dec;7(6):837-47.

40.

A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling.

Korherr C, Hofmeister R, Wesche H, Falk W.

Eur J Immunol. 1997 Jan;27(1):262-7.

PMID:
9022028
41.
42.

'Funnel light' photography of metallic objects (designed by Leon J. LeBeau).

Wesche H.

J Audiov Media Med. 1995 Dec;18(4):163-4. No abstract available.

PMID:
8758232
43.

Some simplified methods for the photography of equipment and apparatus.

Wesche H.

J Audiov Media Med. 1992 Jul;15(3):117-20.

PMID:
1460241
44.

Tetanus immunity in older adults.

Wesche HA, Overfield T.

Public Health Nurs. 1992 Jun;9(2):125-7.

PMID:
1508826
45.

Transdermal delivery of mepindolol and propranolol in normal man. 1st communication: study design, clinical and pharmacodynamic aspects.

de Mey C, Enterling D, Ederhof M, Wesche H, Osterwald H.

Arzneimittelforschung. 1989 Nov;39(11A):1505-8.

PMID:
2576200
46.

Pharmacokinetics and pharmacodynamics of single oral doses of ibopamine, quinidine and their combination in normal man.

de Mey C, Enterling D, Brendel E, Wesche H.

Eur J Clin Pharmacol. 1988;34(4):415-8.

PMID:
3402527
47.

Temelastine, a novel histamine H1-receptor antagonist, does not induce oxidative hepatic enzyme activity in man.

de Mey C, Meineke I, Wesche H.

Eur J Drug Metab Pharmacokinet. 1987 Jan-Mar;12(1):65-9.

PMID:
2886338

Supplemental Content

Loading ...
Support Center